The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors
Open accessThe DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
Abstract
Cancer cells bearing distinct KRAS mutations exhibit variable sensitivity to SHP2 inhibitors (SHP2i). Here we show that cells harboring KRAS Q61H are uniquely resistant to SHP2i, and investigate the underlying mechanisms using biophysics, molecular dynamics, and cell-based approaches. Q61H mutation impairs intrinsic and GAP-mediated GTP hydrolysis, and impedes activation by SOS1, but does not alter tyrosyl phosphorylation. Wild-type and Q61H-mutant KRAS are both phosphorylated by Src on Tyr32 and Tyr64 and dephosphorylated by SHP2, however, SHP2i does not reduce ERK phosphorylation in KRAS Q61H cells. Phosphorylation of wild-type and Gly12-mutant KRAS, which are associated with sensitivity to SHP2i, confers resistance to regulation by GAP and GEF activities and impairs binding to RAF, whereas the near-complete GAP/GEF-resistance of KRAS Q61H remains unaltered, and high-affinity RAF interaction is retained. SHP2 can stimulate KRAS signaling by modulating GEF/GAP activities and dephosphorylating KRAS, processes that fail to regulate signaling of the Q61H mutant.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Codon 61 mutations such as Q61H strongly impair intrinsic GTP hydrolysis and exhibit relative independence from upstream SOS1/SHP2 regulation, limiting sensitivity to certain upstream-targeted therapies [13,16].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [13]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For example, KRAS Q61H exhibits marked resistance to SHP2-mediated regulation, thereby limiting sensitivity to SHP2 inhibition [13,50].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [13]
In the citing paper
“KRASG12C-mediated GTP hydrolysis is, however, refractory to (and might even be inhibited by) RAS-GAPs, whereas some other KRAS variants (G12D, G12A, G12R and G12V) might remain responsive to GAPs50. Even with GAP stimulation, the GTPase activity of KRASQ61L and KRASG61H is limited51.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [51]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
VMD: visual molecular dynamics
Humphrey, W., Dalke, A., & Schulten, K. (1996) · Journal of Molecular Graphics · doi:10.1016/0263-7855(96)00018-5 · Cited by 66,952 · cited 1×
“RAS/RAF binding was assessed using the RAS activation assay kit from Millipore (17-218).”
MethodParticle mesh Ewald: An N ⋅log( N ) method for Ewald sums in large systems
Darden, T., York, D., & Pedersen, L. (1993) · The Journal of Chemical Physics · doi:10.1063/1.464397 · Cited by 30,546 · cited 1×
“RAS/RAF binding was assessed using the RAS activation assay kit from Millipore (17-218).”
MethodNMRPipe: A multidimensional spectral processing system based on UNIX pipes
Delaglio, F., Grzesiek, S., Vuister, G., Zhu, G., Pfeifer, J., & Bax, A. (1995) · Journal of Biomolecular NMR · doi:10.1007/bf00197809 · Cited by 15,965 · cited 1×
“RAS/RAF binding was assessed using the RAS activation assay kit from Millipore (17-218).”
MethodAll-Atom Empirical Potential for Molecular Modeling and Dynamics Studies of Proteins
MacKerell, A. D., Bashford, D., Bellott, M., Dunbrack, R. L., Evanseck, J. D., Field, M. J., Fischer, S., Gao, J., Guo, H., Ha, S., et al. (1998) · The Journal of Physical Chemistry B · doi:10.1021/jp973084f · Cited by 14,311 · cited 1×
“RAS/RAF binding was assessed using the RAS activation assay kit from Millipore (17-218).”
MethodCHARMM‐GUI: A web‐based graphical user interface for CHARMM
Jo, S., Kim, T., Iyer, V. G., & Im, W. (2008) · Journal of Computational Chemistry · doi:10.1002/jcc.20945 · Cited by 9,284 · cited 1×
“RAS/RAF binding was assessed using the RAS activation assay kit from Millipore (17-218).”
MethodConstant pressure molecular dynamics algorithms
Martyna, G. J., Tobias, D. J., & Klein, M. L. (1994) · The Journal of Chemical Physics · doi:10.1063/1.467468 · Cited by 5,804 · cited 1×
“RAS/RAF binding was assessed using the RAS activation assay kit from Millipore (17-218).”
MethodBest, R. B., Zhu, X., Shim, J., Lopes, P. E. M., Mittal, J., Feig, M., & MacKerell, A. D. (2012) · Journal of Chemical Theory and Computation · doi:10.1021/ct300400x · Cited by 4,532
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621 · cited 1×
“RAS/RAF binding was assessed using the RAS activation assay kit from Millipore (17-218).”
MethodScalable molecular dynamics on CPU and GPU architectures with NAMD
Phillips, J. C., Hardy, D. J., Maia, J. D. C., Stone, J. E., Ribeiro, J. V., Bernardi, R. C., Buch, R., Fiorin, G., Hénin, J., Jiang, W., et al. (2020) · The Journal of Chemical Physics · doi:10.1063/5.0014475 · Cited by 3,144 · cited 1×
“RAS/RAF binding was assessed using the RAS activation assay kit from Millipore (17-218).”
MethodMoffitt, R. A., Marayati, R., Flate, E. L., Volmar, K. E., Loeza, S. G. H., Hoadley, K. A., Rashid, N. U., Williams, L. A., Eaton, S. C., Chung, A. H., et al. (2015) · Nature Genetics · doi:10.1038/ng.3398 · Cited by 2,194 · cited 1×
“RAS/RAF binding was assessed using the RAS activation assay kit from Millipore (17-218).”
MethodSelf-citation
Research works printed but not linked: 2
- Lu, H. et al. SHP2 inhibition overcomes RTK-mediated pathway re-activation in KRAS mutant tumors treated with MEK inhibitors. Mol. Cancer Ther. https://doi.org/10.1158/1535-7163.MCT-18-0852 (2019). · DOI · Paper page
- Nichols, R. J. et al. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers. Nat. Cell Biol. https://doi.org/10.1038/s41556-018-0169-1 (2018). · DOI · Paper page
Cited by
The current state of the art and future trends in RAS-targeted cancer therapies
Punekar, S. R., Velcheti, V., Neel, B. G., & Wong, K.-K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00671-9 · Cited by 549
Classification of KRAS -Activating Mutations and the Implications for Therapeutic Intervention
Johnson, C., Burkhart, D. L., & Haigis, K. M. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0035 · Cited by 121
SHP2: A Pleiotropic Target at the Interface of Cancer and Its Microenvironment
Sodir, N. M., Pathria, G., Adamkewicz, J. I., Kelley, E. H., Sudhamsu, J., Merchant, M. A., Chiarle, R., & Maddalo, D. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0383 · Cited by 109
“As blocking SHP2 disrupts SOS1-mediated RAS-GTP loading, SHP2i are expected to show an antiproliferative activity in tumors where RAS cycling is at least partially intact and to have no effect when RAS is locked in an active state, as in the Q61 mutants (92).”
BackgroundTargeting KRAS mutations in pancreatic cancer: opportunities for future strategies
Linehan, A., O’Reilly, M., McDermott, R., & O'Kane, G. M. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1369136 · Cited by 60
Ricciuti, B., Son, J., Okoro, J. J., Mira, A., Patrucco, E., Eum, Y., Wang, X., Paranal, R., Wang, H., Lin, M., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2719 · Cited by 42
Metadata
- Authors
- Gebregiworgis, T., Kano, Y., St-Germain, J., Radulovich, N., Udaskin, M. L., Mentes, A., Huang, R., Poon, B. P. K., He, W., Valencia-Sama, I., Robinson, C. M., Huestis, M., Miao, J., Yeh, J. J., Zhang, Z.-Y., Irwin, M. S., Lee, J. E., Tsao, M.-S., Raught, B., Marshall, C. B., Ohh, M., & Ikura, M.
- Affiliations
- University Health Network (CA)
- Tokyo Medical and Dental University (JP)
- University of Toronto (CA)
- Purdue University West Lafayette (US)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Marshall, Christopher B.
- Ohh, Michael
- Ikura, Mitsuhiko
- ORCID
- Gebregiworgis, Teklab
- Kano, Yoshihito
- Radulovich, Nikolina
- Udaskin, Molly L.
- Huang, Richard
- Poon, Betty P. K.
- He, Wenguang
- Valencia-Sama, Ivette
- Robinson, Claire M.
- Huestis, Melissa
- Miao, Jinmin
- Yeh, Jen Jen
- Zhang, Zhong-Yin
- Irwin, Meredith S.
- Lee, Jeffrey E.
- Tsao, Ming-Sound
- Raught, Brian
- Marshall, Christopher B.
- Ohh, Michael
- Ikura, Mitsuhiko
- Venue
- Nature Communications
- Published
- 2021-11-01
- Volume
- 12
- Issue
- 1
- Pages
- 6274-6274
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC8560773
- OpenAlex
- W3210161753
- Cited by
- 49
- References
- 83
- Citations by year
- 2026: 9 · 2025: 9 · 2024: 13 · 2023: 8 · 2022: 10
- FWCI
- 2.43
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health
- Canadian Institutes of Health Research (133694_1, FDN‐1542284, PJT-166005,)
- Canadian Cancer Society Research Institute (703209)
- Japan Society for the Promotion of Science (19K23909, 166005)
- National Cancer Institute (R01CA207288, R01CA069202)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- SHP2 inhibitors, drug resistance, GTP hydrolysis, SOS1, GTPase-activating protein, guanine nucleotide exchange factor, ERK1/2 phosphorylation, Src kinase, KRAS signaling
- MeSH terms
- Enzyme Inhibitors, Guanosine Triphosphate, Humans, Lung Neoplasms, Gene Expression Regulation, Neoplastic, Proto-Oncogene Proteins p21(ras), src-Family Kinases, Mutation, Missense, Cell Line, Tumor, raf Kinases, Protein Tyrosine Phosphatase, Non-Receptor Type 11
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors. https://app.cochat.ai/papers/10.1038/s41467-021-26526-y
- The paper
- Gebregiworgis, T., Kano, Y., St-Germain, J., Radulovich, N., Udaskin, M. L., Mentes, A., Huang, R., Poon, B. P. K., He, W., Valencia-Sama, I., Robinson, C. M., Huestis, M., Miao, J., Yeh, J. J., Zhang, Z.-Y., Irwin, M. S., Lee, J. E., Tsao, M.-S., Raught, B., . . . Ikura, M. (2021). The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors. Nature Communications. https://doi.org/10.1038/s41467-021-26526-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.